MUSTBIO
PrivateLast Round
Series C
Mar 14, 2026
Est. Valuation
$63.1M
Total Funding Raised
$156.7M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
MUSTBIO is a biotechnology company that develops multi-specific antibody-based cancer immunotherapies using its proprietary BICSTA™ and STARKINE™ platforms.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Drug Discovery, Pharma Supply Chain
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MUSTBIO Comparables
Compare MUSTBIO with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Geno Technology, Inc. | 78% | |
| Vector Laboratories | 77% | |
| Shanghai Haoyuan Chemexpress Co., Ltd. | 77% |
MUSTBIO Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Mar 14, 2026 | ||||
| Series C | Mar 13, 2026 | ||||
| Follow-on Offering | Feb 10, 2025 | ||||
| Private Placement | Oct 25, 2024 | ||||
| Private Placement | Jun 21, 2024 | ||||
Follow-on Offering | May 2, 2024 |
MUSTBIO Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Runway Growth Capital | Debt |
| ROTH Capital Partners | Follow-on Offering |
| National Cancer Institute | Grant |
| BNH INVESTMENT | Series C |
| Korea Investment Partners | Series C, Series B, Series A |
| NIH RADx | Grant |
| H.C. Wainwright & Co. | Private Placement, Follow-on Offering |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 20, 2026
Monthly visitors grew 95% MoM, from 3.2K to 6.2K.
- Feb 10, 2025
Raised $8M in a follow-on offering.
MUSTBIO Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about MUSTBIO's valuation, stock price, and market status.
Is MUSTBIO a public or private company?
MUSTBIO is a private company.
What is the current stock price of MUSTBIO?
MUSTBIO is a private company with no public stock price. No recent secondary market data is available.
How much is MUSTBIO worth (valuation)?
MUSTBIO's valuation is estimated at $63.1M based on funding round data.
Can I buy MUSTBIO stock?
MUSTBIO shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was MUSTBIO's last funding round?
MUSTBIO's most recent funding round was Series C on March 14, 2026.
Who are the main investors in MUSTBIO?
Key investors in MUSTBIO include BNH INVESTMENT, Korea Investment Partners, Premier Partners, Wonik Investment Partners, San-eun Investment.
Will MUSTBIO IPO soon?
No public IPO plans have been announced for MUSTBIO.
How can I track MUSTBIO secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor MUSTBIO's secondary market activity and sign up for updates.